GT BIOPHARMA, INC.

Analyst Reco. GT Biopharma, Inc. Euronext Paris

Equities

GTBP

US36254L3087

Market Closed - Euronext Paris Other stock markets 05:30:03 2020-12-24 am EST			5-day change	1st Jan Change
0.55 ^EUR	-86.52%		-96.67%	-99.80%

Jun. 27	GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650	MT
Jun. 27	GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EF Hutton Starts GT Biopharma at Hold With $2 Price Target	23-01-05	MT
HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating	22-09-13	MT
Roth Capital Cuts GT Biopharma to Neutral From Buy, Price Target to $3 From $9	22-08-12	MT
B. Riley Lowers GT Biopharma's Price Target to $18 from $26 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
GT BIOPHARMA : B. Riley Raises GT Biopharma's PT to $26 from $21, Notes Steady Progress of Dose-Escalation Trial of Lead Asset GTB-3550; Keeps Buy Rating	21-06-24	MT
GT BIOPHARMA : HC Wainwright Starts GT Biopharma at Buy With $25 Price Target	21-05-24	MT
GT BIOPHARMA : B. Riley Starts GT Biopharma at Buy with $21 PT, Says Solid Tumor Indications Represent Source of Potential Upside	21-04-13	MT
GT BIOPHARMA : Roth Capital Starts GT Biopharma at Buy With $25 Price Target	21-03-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Secure my Investments

fermer